About Us

Pathios Therapeutics is an early-stage drug discovery company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of acid-sensing GPCRs in Th17 cells and tumour-associated macrophages (TAMs). We are currently engaged in a fully-enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility in a range of autoimmune conditions as well as in certain cancers. We are also more broadly interested in acid-sensing receptors in the immune system and their potential exploitation as targets for bringing about therapeutic benefit in a range of diseases.

Pathios employs a cutting edge scientific approach to mapping the signalling of key GPCRs on immune cells based on human genetic insights, transcriptomics and state-of-the-art cellular immunology. By leveraging a range of proprietary insights emerging from this approach Pathios aims to rapidly deliver on the promise of novel therapeutic agents targeting these receptors. We combine a team of experienced scientific leaders with a number of strategic external partnerships to efficiently carry out a range of drug discovery and scientific activities, capitalising on the very latest advances in GPCR drug discovery.

GPCRs Key Facts


Approx. 600 genes encoding GPCRs in the human genome


GPCRs are the largest single protein class targeted by marketed drugs


No approved drugs currently target any of the pH-sensing GPCRs on immune cells

“Pathios is founded on the simple principle that many pathological environments such as inflamed joints or malignant tumours are characterized by an abnormally low pH that signals to local immune cells to fundamentally change their characteristics in a detrimental way for the patient. At the heart of this signalling is a family of acid-sensing GPCRs. Pathios is particularly focused on finding drugs that block GPR65 which is a key member of this family. Human genetic data and cutting-edge transcriptomics tells us that this receptor is a key driver in the emergence of problematic Th17 cells and therefore autoimmune disease. Emerging data also implicates GPR65 in altering the nature of tumour-associated macrophages (TAM) to allow tumour growth and survival.” Tom McCarthy, Executive Chair, Pathios Therapeutics